Figure 1

iNOS upregulation following gp120 exposure was attenuated by Asc-p supplementation. Representative images of control (a), gp120 exposed (b)and gp120 exposed primary mixed human CNS aggregate cultures at 4 weeks in vitro after Asc-p supplementation (c) demonstrate that Asc-p supplementation reduced iNOS upregulation. The cultures were examined by immunohistochemistry for iNOS expression (brown) with a hematoxylin counterstain (blue) for nuclei. (Bar= 40 μm). Quantitative analysis of ten random fields taken from each of the three treatment groups from one culture (d) corroborated the qualitative trend and showed the means of control and Asc-p supplemented groups to be significantly different from cultures treated with gp120. Control and gp120 treated group means were significantly different at p < 0.0001, the means of the gp120 and gp120+Asc-p groups were significantly different at p < 0.0001, and the means of control and gp120+Asc-p supplemented groups were significantly different (p = 0.0001). Error bars: +/- 1 standard error.